Figure 1. (A) Mean change in HbA1C over time in the 24-week treatment period and mean change in (B) FPG, (C) 2-h PPG, and (D) body weight at 24 weeks n is the number of randomized patients with non-missing baseline and Week 24 LOCF values; p-values are for the difference between treatment groups. BL: baseline; DAPA: dapagliflozin; Diff: difference; MET: metformin; SAXA: saxagliptin; CI: confidence interval; FPG: fasting plasma glucose; 2-hr PPG: 2-hour postprandial glucose.
